Safety of Lovastatin/Extended Release Niacin Compared With Lovastatin Alone, Atorvastatin Alone, Pravastatin Alone, and Simvastatin Alone (from the United States Food and Drug Administration Adverse Event Reporting System)

American Journal of Cardiology

Volumn 99, Issue 3, 2007, Pages 379-381

  Alsheikh Ali, Alawi A ^a   Karas, Richard H ^a  

^a Division of Cardiology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

LOVASTATIN PLUS NICOTINIC ACID; MEVINOLIN; NICOTINIC ACID; PRAVASTATIN; SIMVASTATIN; SLO NIACIN; UNCLASSIFIED DRUG;

ARTICLE; COMBINATION CHEMOTHERAPY; DISEASE SEVERITY; DRUG CHOICE; DRUG FATALITY; DRUG FORMULATION; DRUG LABELING; DRUG SAFETY; FOOD AND DRUG ADMINISTRATION; HIGH RISK PATIENT; HUMAN; HYPERLIPIDEMIA; LIVER TOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHABDOMYOLYSIS; UNITED STATES;

ADVERSE DRUG REACTION REPORTING SYSTEMS; ANTILIPEMIC AGENTS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER DISEASES; LOVASTATIN; NIACIN; PRAVASTATIN; PRESCRIPTIONS, DRUG; PREVALENCE; PYRROLES; RETROSPECTIVE STUDIES; RHABDOMYOLYSIS; RISK FACTORS; SIMVASTATIN; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 33846508107     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.08.044     Document Type: Article

References (16)

1. Grundy S.M., Cleeman J.I., Merz C.N., Brewer Jr. H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith Jr. S.C., and Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
2. Mosca L., Appel L.J., Benjamin E.J., Berra K., Chandra-Strobos N., Fabunmi R.P., Grady D., Haan C.K., Hayes S.N., Judelson D.R., et al. Evidence-based guidelines for cardiovascular disease prevention in women. Circulation 109 (2004) 672-693
3. Davidson M.H. Reducing residual risk for patients on statin therapy: the potential role of combination therapy. Am J Cardiol 96 (2005) 3K-13K discussion 34K-35K
4. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med 164 (2004) 697-705
5. Davignon J., Roederer G., Montigny M., Hayden M.R., Tan M.H., Connelly P.W., Hegele R., McPherson R., Lupien P.J., Gagne C., Little A., and Colin P. Comparative efficacy and safety of pravastatin, nicotinic acid and the two combined in patients with hypercholesterolemia. Am J Cardiol 73 (1994) 339-345
6. Hill M.D., and Bilbao J.M. Case of the month: February 1999-54 year old man with severe muscle weakness. Brain Pathol 9 (1999) 607-608
7. Reaven P., and Witztum J.L. Lovastatin, nicotinic acid, and rhabdomyolysis. Ann Intern Med 109 (1988) 597-598
8. Morgan J.M., Capuzzi D.M., and Guyton J.R. A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. Am J Cardiol 82 (1998) 29U-34U discussion 39U-41U
9. McKenney J.M., Proctor J.D., Harris S., and Chinchili V.M. A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients. JAMA 271 (1994) 672-677
10. Alsheikh-Ali A., Abourjaily H.M., and Karas R.H. Relative safety of extended-release niacin versus other niacin formulations (abstr). Circulation 110 (2004) III-813
11. Alsheikh-Ali A.A., Abourjaily H.M., and Karas R.H. Risk of adverse events with concomitant use of atorvastatin or simvastatin and glucose-lowering drugs (thiazolidinediones, metformin, sulfonylurea, insulin, and acarbose). Am J Cardiol 89 (2002) 1308-1310
12. Alsheikh-Ali A.A., and Karas R.H. Adverse events with concomitant use of simvastatin or atorvastatin and thiazolidinediones. Am J Cardiol 93 suppl A9 (2004) 1417-1418
13. Alsheikh-Ali A.A., Kuvin J.T., and Karas R.H. Risk of adverse events with fibrates. Am J Cardiol 94 (2004) 935-938
14. Alsheikh-Ali A.A., and Karas R.H. Adverse events with concomitant amiodarone and statin therapy. Prev Cardiol 8 (2005) 95-97
15. Alsheikh-Ali A.A., Ambrose M.S., Kuvin J.T., and Karas R.H. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 111 (2005) 3051-3057
16. Thompson P.D., Clarkson P., and Karas R.H. Statin-associated myopathy. JAMA 289 (2003) 1681-1690